Business Description
Serina Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US81751A1088
Total Employee Number:
16Description
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.74 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -75.2 | |||||
3-Year EPS without NRI Growth Rate | -89.4 | |||||
3-Year FCF Growth Rate | -85.7 | |||||
3-Year Book Growth Rate | 53.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.23 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.9 | |||||
9-Day RSI | 44.47 | |||||
14-Day RSI | 47.21 | |||||
3-1 Month Momentum % | -26.44 | |||||
6-1 Month Momentum % | -27.82 | |||||
12-1 Month Momentum % | -68.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.18 | |||||
Quick Ratio | 4.18 | |||||
Cash Ratio | 3.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.6 | |||||
Shareholder Yield % | -92.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -465.28 | |||||
ROA % | -170.59 | |||||
ROIC % | -770.76 | |||||
3-Year ROIIC % | -1433.88 | |||||
ROC (Joel Greenblatt) % | -2338.49 | |||||
ROCE % | -276.49 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.32 | |||||
Price-to-Tangible-Book | 2.32 | |||||
EV-to-EBIT | -0.63 | |||||
EV-to-EBITDA | -0.63 | |||||
EV-to-Forward-Revenue | 198.73 | |||||
EV-to-FCF | -0.72 | |||||
| Price-to-Net-Current-Asset-Value | 2.46 | |||||
| Price-to-Net-Cash | 1.97 | |||||
Earnings Yield (Greenblatt) % | -158.73 | |||||
FCF Yield % | -61.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:SER
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Serina Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 105 | ||
| 14-Day RSI | 47.21 | ||
| 14-Day ATR ($) | 0.181039 | ||
| 20-Day SMA ($) | 1.8655 | ||
| 12-1 Month Momentum % | -68.68 | ||
| 52-Week Range ($) | 1.22 - 7.92 | ||
| Shares Outstanding (Mil) | 15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Serina Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Serina Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 137 days | ||
| General meeting for 2026 | 2026-08-14 | In 46 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 43 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.72 (+10.97%) | ||
| Annual report for 2025 | 2026-03-25 | 2.43 (-16.31%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 2.43 (-16.31%) | ||
| 38th Annual Roth Conference | 2026-03-24 11:30 | 3.15 (+16.24%) | ||
| Guidance call for 2026 | 2026-02-04 11:30 | 2.76 (+0.73%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 4.02 (-1.95%) | ||
| H.C. Wainwright 27(th) Annual Global Investment Conference | 2025-09-08 09:30 | 5.09 (-0.59%) |
Show
Entries
Serina Therapeutics Inc Frequently Asked Questions
What is Serina Therapeutics Inc(SER)'s stock price today?
The current price of SER is $1.97. The 52 week high of SER is $7.92 and 52 week low is $1.22.
When is next earnings date of Serina Therapeutics Inc(SER)?
The next earnings date of Serina Therapeutics Inc(SER) is 2026-08-11 Est..
Does Serina Therapeutics Inc(SER) pay dividends? If so, how much?
Serina Therapeutics Inc(SER) does not pay dividend.
Guru Commentaries on AMEX:SER
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Serina Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers